Rotana Alsaggaf1,2, Diane Marie M St George2, Min Zhan2, Ruth M Pfeiffer3, Youjin Wang1, Kathryn R Wagner4,5, Mark H Greene1, Sania Amr2,6, Shahinaz M Gadalla1. 1. Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD. 2. Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD. 3. Biostatistics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD. 4. Hugo W. Moser Research Institute at Kennedy Krieger Institute, Baltimore, MD. 5. Departments of Neurology and Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD. 6. Marlene and Stuart Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, MD.
Abstract
BACKGROUND: Myotonic dystrophy type 1 (DM1) is an inherited trinucleotide repeat disorder in which specific cancers have been implicated as part of the disease phenotype. This study aimed to assess whether cancer risk in DM1 patients is modified by disease severity. METHODS: Using the United Kingdom Clinical Practice Research Datalink (primary care electronic medical records), we identified a cohort of 927 DM1 and a matched cohort of 13 085 DM1-free individuals between January 1, 1988 and February 29, 2016. We used Cox regression models to calculate the hazard ratios (HRs) and 95% confidence intervals (CIs) of organ-specific cancer risks. Analyses were stratified by age at DM1 diagnosis as a surrogate for disease severity. Statistical tests were two-sided. RESULTS: Patients with classic DM1 (age at diagnosis: 11-40 years) were at elevated risk of cancer overall (HR = 1.81; 95% CI = 1.12 to 2.93); cancers of the thyroid (HR = 15.93; 95% CI = 2.45 to 103.64), uterus (HR = 26.76; 95% CI = 2.32 to 309.26), and cutaneous melanoma (HR = 5.98; 95% CI = 1.24 to 28.79) accounted for the excess. In late-onset DM1 patients (age at diagnosis >40 years), a reduced overall cancer risk was observed (HR = 0.53; 95% CI = 0.32 to 0.85), possibly driven by the deficit in hematological malignancies (DM1 = 0 cases, DM1-free = 54 cases; P = .02). The difference between the observed HR for classic and late-onset DM1 was statistically significant (P < .001). CONCLUSIONS: The observed difference in relative cancer risk between classic and late-onset DM1 patients compared with their DM1-free counterparts provides the first evidence that disease severity modifies DM1-related cancer susceptibility. This novel finding may guide clinical management and scientific investigations for the underlying molecular mechanisms in DM-related carcinogenesis.
BACKGROUND: Myotonic dystrophy type 1 (DM1) is an inherited trinucleotide repeat disorder in which specific cancers have been implicated as part of the disease phenotype. This study aimed to assess whether cancer risk in DM1 patients is modified by disease severity. METHODS: Using the United Kingdom Clinical Practice Research Datalink (primary care electronic medical records), we identified a cohort of 927 DM1 and a matched cohort of 13 085 DM1-free individuals between January 1, 1988 and February 29, 2016. We used Cox regression models to calculate the hazard ratios (HRs) and 95% confidence intervals (CIs) of organ-specific cancer risks. Analyses were stratified by age at DM1 diagnosis as a surrogate for disease severity. Statistical tests were two-sided. RESULTS: Patients with classic DM1 (age at diagnosis: 11-40 years) were at elevated risk of cancer overall (HR = 1.81; 95% CI = 1.12 to 2.93); cancers of the thyroid (HR = 15.93; 95% CI = 2.45 to 103.64), uterus (HR = 26.76; 95% CI = 2.32 to 309.26), and cutaneous melanoma (HR = 5.98; 95% CI = 1.24 to 28.79) accounted for the excess. In late-onset DM1 patients (age at diagnosis >40 years), a reduced overall cancer risk was observed (HR = 0.53; 95% CI = 0.32 to 0.85), possibly driven by the deficit in hematological malignancies (DM1 = 0 cases, DM1-free = 54 cases; P = .02). The difference between the observed HR for classic and late-onset DM1 was statistically significant (P < .001). CONCLUSIONS: The observed difference in relative cancer risk between classic and late-onset DM1 patients compared with their DM1-free counterparts provides the first evidence that disease severity modifies DM1-related cancer susceptibility. This novel finding may guide clinical management and scientific investigations for the underlying molecular mechanisms in DM-related carcinogenesis.
Authors: J D Brook; M E McCurrach; H G Harley; A J Buckler; D Church; H Aburatani; K Hunter; V P Stanton; J P Thirion; T Hudson Journal: Cell Date: 1992-04-17 Impact factor: 41.582
Authors: M Mahadevan; C Tsilfidis; L Sabourin; G Shutler; C Amemiya; G Jansen; C Neville; M Narang; J Barceló; K O'Hoy Journal: Science Date: 1992-03-06 Impact factor: 47.728
Authors: Robert J Osborne; Xiaoyan Lin; Stephen Welle; Krzysztof Sobczak; Jason R O'Rourke; Maurice S Swanson; Charles A Thornton Journal: Hum Mol Genet Date: 2009-02-17 Impact factor: 6.150
Authors: Christine M Mueller; James E Hilbert; William Martens; Charles A Thornton; Richard T Moxley; Mark H Greene Journal: Cancer Causes Control Date: 2009-12 Impact factor: 2.506
Authors: Fiona L M Norwood; Chris Harling; Patrick F Chinnery; Michelle Eagle; Kate Bushby; Volker Straub Journal: Brain Date: 2009-09-18 Impact factor: 13.501
Authors: Cecilia Higgs; James E Hilbert; Libby Wood; William B Martens; Chiara Marini-Bettolo; Nikoletta Nikolenko; Rotana Alsaggaf; Hanns Lochmüller; Richard T Moxley; Mark H Greene; Youjin Wang; Shahinaz M Gadalla Journal: Front Neurol Date: 2019-10-11 Impact factor: 4.003
Authors: Rotana Alsaggaf; Diane Marie M St George; Min Zhan; Ruth M Pfeiffer; Youjin Wang; Lesley A Anderson; Zhiwei Liu; Jill Koshiol; Andrew J Bauer; Kathryn R Wagner; Mark H Greene; Sania Amr; Shahinaz M Gadalla Journal: Ann Clin Transl Neurol Date: 2019-07-26 Impact factor: 4.511
Authors: Eva Alegre-Cortés; Alberto Giménez-Bejarano; Elisabet Uribe-Carretero; Marta Paredes-Barquero; André R A Marques; Mafalda Lopes-da-Silva; Otília V Vieira; Saray Canales-Cortés; Pedro J Camello; Guadalupe Martínez-Chacón; Ana Aiastui; Roberto Fernández-Torrón; Adolfo López de Munain; Patricia Gomez-Suaga; Mireia Niso-Santano; Rosa A González-Polo; José M Fuentes; Sokhna M S Yakhine-Diop Journal: Cells Date: 2022-09-27 Impact factor: 7.666
Authors: Rotana Alsaggaf; Ruth M Pfeiffer; Youjin Wang; Diane Marie M St George; Min Zhan; Kathryn R Wagner; Sania Amr; Mark H Greene; Shahinaz M Gadalla Journal: Int J Cancer Date: 2019-12-19 Impact factor: 7.316